Increased NET levels have been observed in the serum of both nonalcoholic steatohepatitis (NASH) [245] and HCC patients [195], suggesting that PAD4 may be involved in the progression of hepatitis to liver cancer and contribute to the malignant transformation of liver disease into HCC. This evidence concerns the gene PADI4 and hepatocellular carcinoma.